Announcements Trials
Browse Landscape

Phase

Phase 3 11Phase 1 4Phase 2 3Phase 4 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Head & Neck 1

Conditions

Prostatic Neoplasms 2Salivary Gland Neoplasms 1

Interventions

Specimen Handling 132Magnetic Resonance Spectroscopy 107Biopsy 79pembrolizumab 66Nivolumab 63Carboplatin 62Cisplatin 60Cyclophosphamide 56Paclitaxel 47Radiotherapy 37Gemcitabine 37Bevacizumab 36Dexamethasone 33Pemetrexed 28Rituximab 27Fluorouracil 27Doxorubicin 26olaparib 25Injections 25fludarabine 24durvalumab 24atezolizumab 24Radiation 24Ipilimumab 23Docetaxel 23Oxaliplatin 22Cytarabine 22venetoclax 21Vincristine 21Taxes 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × apalutamide × 30 days × Clear all
NCT04325828 2026-06-05

YATAGARASU

Janssen Pharmaceutical K.K.

Phase 2 Active not recruiting
31 enrolled 15 charts
Head & Neck

Salivary Gland Neoplasms

NCT04530552 2026-05-29

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

National Cancer Institute (NCI)

Phase 2 Active not recruiting
34 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

NCT04947254 2026-05-15

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡